Q25 – – $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting strong demand – – $45.8 million Niktimvo™ (axatilimab-csfr) net ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Anthropologist Christopher Bae has recently suggested we add two new species of ancient human to our family tree. The plans break the conventions for how species should be named – but Bae argues the r ...

Session Name: 631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN Session Date and Time: December 6, 2025; 9:30 AM – 11:00 AM ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B ...

VYJUVEK is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa with mutation(s) ...

Background Fabry disease (FD) is an X linked lysosomal disorder with ventricular myocardial involvement that drives morbidity and mortality. Early diagnosis of cardiac involvement can be difficult.

The condition arises from mutations in the CPS1 gene ... pulmonary arterial hypertension and HIV, as well as grants for basic ...

If youre a fan of spicy foods, you know they definitely have an effect on your body. You may break out into a sweat after ...

Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...